The ErbB3 receptor and the downstream signaling kinase Akt are implicated in proliferation of lung adenocarcinoma cells. Inhibition by siRNAs to ErbB3 and Akt isoforms 1, 2 and 3 was utilized to investigate the contribution of these molecules to tumor survival, spreading and invasiveness, and the roles of specific Akt isoforms. ErbB3 siRNA stably and dose-dependently suppressed ErbB3 protein for 2 days or more, and reduced cell numbers, by both suppressing cell cycle and causing apoptosis and necrosis. It also inhibited soft agar growth, cell motility and migration, and invasiveness. Akt1, 2 and 3 siRNAs had similar suppressive effects on cell number, apoptosis/ necrosis and soft agar growth. However, although Akt1 siRNA had no effect on cell migration or invasion, Akt2 siRNA effectively suppressed both activities, and Akt3 siRNA had moderate effectiveness. In A549 cells, ErbB3 is indicated as having major effects on cell division, survival, motility, migration and invasiveness. All three Akt isoforms are to varying degrees involved in these cell behaviors, with Akt2 especially implicated in migration and invasion. ErbB3 and the Akts are promising targets for therapy, and siRNAs may be useful for this purpose.
Introduction
ErbB3 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases. Other members of this family include EGFR (also known as ErbB1), ErbB2 and ErbB4. EGFR responds to ligands such as transforming growth factor alpha (TGFa) or epidermal growth factor. Heregulin (Hrg) is a ligand for ErbB3 and ErbB4. There is no known ligand for ErbB2 (Tzahar and Yarden, 1998) . ErbB3 is unique among its family members in that it does not have any intrinsic kinase activity (Guy et al., 1994) . Therefore, ErbB3 is active only as a heterodimer complex, and ErbB3 has highest affinity for ErbB2; the ErbB2/ErbB3 heterodimer is the most effective complex for activation of downstream pathways (Yarden and Sliwkowski, 2001; Citri et al., 2003) . Downstream, ErbB3 recruits phosphatidylinositol 3 kinase (PI3K) directly, as it has at least seven binding sites for the regulatory domain (p85) of PI3K (Soltoff et al., 1994) . Ligand-induced multiple signaling pathways from these receptors control critical cellular processes. Deregulation of this signaling is a feature commonly found in many cancers, resulting in potentiation of proliferation, cell survival and motility of tumor cells.
EGFR and ErbB2 are widely implicated in lung cancer. Immunohistochemical studies have indicated overexpression of EGFR in 65-84% of non-small cell lung carcinoma (NSCLC), especially squamous cell carcinoma (Veale et al., 1987) , and of ErbB2 in 30% of NSCLC patients and in up to 100% of lung adenocarcinomas (Tateishi et al., 1991) . Overexpression of ErbB3 has been reported in some lung adenocarcinomas (Poller et al., 1992) and associated with a poor prognosis (Yi et al., 1997) . Coexpression of ErbB3 with other EGFR family members was indicative of tumor recurrence . The expression of the proliferation-associated marker Ki-67 at a higher frequency in ErbB3-positive NSCLC cases than in ErbB3-negative tumors was suggestive of a contribution of ErbB3 to aggressive behavior (Hilbe et al., 2003) .
Mounting evidence documents the presence of the ErbB2/ErbB3 heterodimer in a variety of tumors including lung (Sithanandam et al., 2003; Gollamudi et al., 2004) , breast (Holbro et al., 2003) , colorectal (Venkateswarlu et al., 2002) and stomach (Noguchi et al., 1999) . A transgenic mouse model for lung tumor also suggested the importance of the ErbB2/ErbB3 heterodimer in lung tumorigenesis: mice doubly transgenic for ErbB3 and ErbB2 had shorter lung tumor latency compared with the single transgenic ErbB3 mice (Zhou et al., 2002) .
Downstream of the ErbB2/ErbB3 heterodimer, the PI3K/Akt pathway is induced and plays a key role in proliferation, survival and invasion of breast, ovarian and colon cancer cells (Arboleda et al., 2003; Holbro et al., 2003; Jackson et al., 2004) . We have recently established that the ErbB2/ErbB3 heterodimer is involved in the growth of human lung adenocarcinoma cells through the activation of PI3K and Akt (Sithanandam et al., 2003) . A growing body of evidence implicates Akt in lung tumorigenesis. Higher levels of phosphorylated Akt were observed in premalignant and malignant human bronchial epithelial cells (Chun et al., 2003) , and in bronchial hyperplasia, squamous metaplasia and dysplasia (Tsao et al., 2003; Balsara et al., 2004) . Akt overexpression was correlated with poor prognosis in one study (David et al., 2004) , although not in another (Tsao et al., 2003) . Constitutive Akt activity found in NSCLC cell lines was associated with cell survival and therapeutic resistance (Brognard et al., 2001) . Akt activation has been found among the downstream effects of mutant K-ras (Okudela et al., 2004) and in cellular changes induced by tobacco carcinogens (West et al., 2004) . Recent results showing a correlation between EGFR and TGFa expression with phospho-Akt (pAkt) levels in NSCLC (Mukohara et al., 2004) confirm Akt as a downstream transmitter of signals from the ErbB receptors.
There are three isoforms of Akt, and all are expressed in lung cancer cells (Zinda et al., 2001) . Although studies are starting to appear where functional redundancies and differences among these isoforms have been examined in cancers, for example, colon cancer (Roy et al., 2002) , there are no reports on the relative contributions of Akt1, 2 and 3 in lung cancer.
The EGFR family members are being targeted in clinical trials for lung cancer (Raben et al., 2004) . A small molecular weight inhibitor against EGFR, gefitinib (Iressa, ZD1839), has given variable response, including reduced disease-related symptoms (Natale, 2004) . Levels of neither total nor phosphorylated EGFR correlated with gefitinib response in NSCLC clinical trials (Lynch et al., 2004; Paez et al., 2004) or in NSCLC cell lines in culture (Ono et al., 2004) . However, in a small subset of NSCLC, a dramatic response was observed for those cancers with a gain-of-function somatic mutation in the ATP binding pocket of the EGFR gene (Lynch et al., 2004; Paez et al., 2004) . These mutations were more frequent in adenocarcinomas (21%) than in other NSCLC (2%), more frequent in women than in men, and more frequent in patients from Japan than from the United States (Paez et al., 2004) . Only NSCLC cell lines with the EGFR mutant gene were sensitive to gefitinib (Paez et al., 2004) .
These results confirm that EGFR-initiated signaling pathways can be successfully targeted in lung cancers, if understood in sufficient detail. Importantly, sensitivity of NSCLC cells to gefitinib required dependence on EGFR for Akt and MAP kinase activation and continued cell growth and survival (Ono et al., 2004) . This observation, together with the body of data implicating Akt in lung cancer (above), suggests that Akt and upstream activators such as ErbB3 could be useful therapeutic targets. Interestingly, we have previously demonstrated that ErbB3 antisense blocked the proliferation of H441 (Sithanandam et al., 2003) , a lung adenocarcinoma cell line expressing only wild-type EGFR, which has recently been shown to be gefitinib insensitive (Paez et al., 2004) . Thus, ErbB3, rather than EGFR, may be the driving force for proliferation and survival of many lung cancers. We have now extended our studies to another gefitinib-insensitive cell line, A549 (Ono et al., 2004) , and demonstrate the importance of ErbB3 and of Akt for lung cell malignancy, using a powerful tool, RNA interference. We also show that ErbB3 promotes motility and invasion as well as survival of these lung adenocarcinoma cells, and find that, of the three Akt isoform, Akt2 was particularly effective in promoting invasion.
Results
ErbB3 siRNAs suppress ErbB3 expression in human lung adenocarcinoma cell lines H441, H1373 and A549 Synthetic siRNAs directed against three different regions of ErbB3 (ErbB3.1, ErbB3.2, ErbB3.3) were tested for their ability to suppress ErbB3 expression in human non-small cell lung adenocarcinoma cells H441, H1373 and A549 by Western blotting. ErbB3.1 and ErbB3.3 siRNAs were more effective than ErbB3.2. An approximate 80% reduction in protein levels was observed within 24-48 h of transfection in all three cell types ( Figure 1) . The suppression persisted 72 h posttransfection (data not shown). Downregulation of ErbB3 was not observed in cells transfected with a control nonsilencing siRNA or in mock-transfected Figure 1 Sequence-specific inhibition of ErbB3 protein expression by synthetic siRNAs ErbB3.1, ErbB3.2 and ErbB3.3 in human lung adenocarcinoma cells H1373, H441 and A549. A nonsilencing siRNA-transfected (control NS), mock-transfected (mock, all reagents except for siRNA) and cells without treatment (NT) were used as controls. Cells were transfected with 120 pmol/ml of the indicated siRNAs and 48 h post-transfection, the cells were lysed and 50 mg of total lysate protein was used for detection of ErbB3 by Western blotting. The blots were stripped and reprobed with antibody to p85 PI3K, which served as a loading control. The illustrated experiment is representative of three The Annexin V-fluorescein isothiocyanate (FITC) assay was utilized to determine whether the reduction in cell number was due to apoptosis or necrosis. The percent dead cells was increased by approximately 15% (Figure 2c ), with about two-thirds of this increase due to apoptosis and one-third due to necrosis with 120 pmol/ ml siRNA treatment (a threefold increase in apoptosis compared to mock-transfected cells; Figure 2d ). The remainder of the suppressive effect appeared to involve cell cycle arrest in S/G2: compared with mock-transfected cells, treatment with ErbB3.1 or 3.3 siRNA resulted in a 10-20% reduction in percentages in G1 and increased percentages in S/G2 (data not shown). Thus the ErbB3 siRNAs reduced the number of viable cells in part by killing, and in part by suppression of the cell cycle.
The proapoptotic effects of the ErbB3.1 and ErbB3.3 siRNAs were studied further as a function of dose. The apoptotic sub-G1 population increased with increasing concentrations of siRNA (Figure 3a) , with up to a fourfold increase with 120 pmol/ml and a ninefold ) were plated on 96-well plates, transfected 24 h later with 12 pmol/100 ml of ErbB3 siRNAs and subjected to MTT assay 48 h post-transfection. Each bar represents the mean value of three identical wells from an experiment representative of three trials with different cell cultures. For all experiments combined, averages for all three ErbB3 siRNA constructs were significantly less than for mock-transfected, and averages for ErbB3.1 and 3.2 siRNAs were significantly more than those for ErbB3. increase with 240 pmol/ml ErbB3 siRNA treatment compared to mock-transfected cells after 48 h. There was no significant increase in apoptosis in nonsilencing siRNA-treated cells compared to mock-transfected cells (data not shown). These dose-dependent effects of the ErbB3 siRNAs correlated well with reduction in ErbB3 protein (Figure 3b) .
The proapoptotic effect of ErbB3 siRNA was confirmed by measurement of cleaved PARP, an established early biochemical indicator of apoptosis. Cleaved PARP was increased in ErbB3 siRNA-treated A549 cells compared to the mock-transfected, nonsilencing siRNA, and untreated control cells (Figure 3c ). These results suggest that ErbB3 is involved in cell survival of lung adenocarcinoma cells. Cleaved PARP was also upregulated in ErbB3 siRNA-treated H441 and H1373 cells (data not shown).
ErbB3 siRNA inhibits the ability of A549 cells to grow in soft agar
We next investigated the effect of ErbB3 siRNA treatment on anchorage-independent growth by assaying colony formation on soft agar, an indicator of malignancy. Soft agar colonies were scanned and computed using Proimage scanning software. ErbB3.1, and ErbB3.3 siRNA, respectively, caused a 30 and 45% reduction in the number of soft agar colonies compared to nonsilencing siRNA-or mock-treated cells (Figure 4a and b). The reduction in ErbB3 protein in samples of cells assayed at the time of soft agar seeding correlated well with the reduction in colony number (Figure 4c ). ErbB3.3 was somewhat more effective than ErbB3.1. ErbB3.2 did not reduce the number of soft agar colonies (not shown) and had only a small effect on ErbB3 protein ( Figure 4c ) and so serves as an internal control for the sequence specificity of the effects in this experiment.
ErbB3 depletion affects cell spreading, motility and invasion of A549 cells
Since ErbB3 expression is associated with poor prognosis in lung cancer patients, we hypothesized that ErbB3 function may be critical for cell migration, which is essential for invasion and metastasis. A549 cells are known for their invasive growth potential and exhibit enhanced growth on basement membranes such as Matrigel, with typical cell spreading and branching. We evaluated the effect of siRNA-mediated ErbB3 depletion on cell spreading on Matrigel. Mock-or nonsilencing siRNA-treated cells retained the typical cell spreading and branching, displaying this phenotype within 6 h after plating ( Figure 5 ). In contrast, most of the ErbB3 siRNA-treated cells remained round even after prolonged incubation (24-30 h) and formed clusters, while the control cells continued to maintain a prominent lattice-like network. Similar results were obtained with both thin-layer and thick-layer Matrigel. Thus, ErbB3 function appears essential for cell spreading.
We next examined the effect of ErbB3 depletion on basal and serum-induced migration of A549 cells. PET membranes in transwell chambers were used for this analysis. ErbB3 depletion reduced the ability of A549 cells to migrate through the pores compared to nonsilencing siRNA-or mock-treated cells (Figure 6a and b). Migration was reduced by more than 50% by both ErbB3.1 and 3.3 siRNAs. Cell migration is a process that promotes tumor invasion. Therefore, we assayed for cell invasion using Matrigel-coated transwell chambers. ErbB3 siRNA treatment strongly inhibited cell invasion, by 60%, after 24 h compared to mocktreated or untreated A549 cells (Figure 6c and d). These results suggest that ErbB3 plays a role in promoting the invasive phenotype of A549 adenocarcinoma cells. 
Isoform-specific Akt siRNAs inhibit Akt1, Akt2 and Akt3 in A549 cells
We have recently provided indirect evidence for Akt as a downstream effector molecule of ErbB3 in lung adenocarcinoma cells (Sithanandam et al., 2003) . All three isoforms of Akt are expressed in A549 cells. These Akt isoforms are activated by the phosphorylation of conserved Thr and Ser residues. We used the siRNA approach to identify which of these isoform(s) are involved in ErbB3-mediated signaling. A commercially available pan Akt antibody differentiated Akt1 and Akt2 proteins by their mobility pattern on an 8% gel (Figure 7a , top). Akt3 migrated very close to Akt1; therefore, an isoform-specific Akt3 antibody was used for its detection on Western blotting (Figure 7a , center). Akt1.1 siRNA reduced the band, which includes Akt1 and 3. Since specific anti-Akt3 did not reveal any decrease in this band (Figure 7a , bottom), we conclude that Akt1.1 siRNA specifically affects Akt1 protein.
Akt2.2 and Akt3 siRNAs specifically downregulated their corresponding proteins without affecting other isoforms. Although Akt1.1 and 2.2 siRNAs reduced their respective proteins, and had some pronounced cell effects (see below), they had no effect on Ser473 pAkt, as the sum of all isoforms, in unstimulated A549 cells (Figure 7b ). This was observed in repeated independent trials. This may indicate that there was in fact a decrease in phosphorylation in each case, accompanied by a compensatory increase in phosphorylation in the remaining two isoforms. Alternatively, under these conditions, Akt1 and Akt2 may be activated predominantly by phosphorylation on tyrosine residues Conus et al., 2002) ; no antibodies to these forms of pAkt are available. Reduction in basal Ser473 pAkt levels was observed only in cells treated with siRNA specific for Akt3, indicating that Akt3 is Values represent mean7s.e. from three independent experiments for each siRNA treatment. Percent colonies were significantly reduced by both ErbB3.1 and 3.3 siRNAs vs mock transfected, and the ErbB3.3 siRNA was more effective than the ErbB3.1 siRNA (P ¼ 0.028). (c) ErbB3 protein expression in the transfectants used for soft agar assay. Reduction in the number of soft agar colonies correlated with the reduction in ErbB3 protein levels 
siRNA-mediated Akt protein depletion increases apoptosis and blocks soft agar growth in A549 cells
The roles of the individual Akt isoforms were investigated by studying the effects of the isoform-specific siRNAs on cell number and on apoptosis, after Hrgb treatment of A549 cells. There was a 40-50% reduction in the number of living cells 24-48 h after treatment with 120 pmol siRNA for Akt1, Akt2 or Akt3, as shown by the Trypan blue exclusion assay (Figure 8a ). The Annexin V-FITC assay revealed a 15-20% increase in dead cells (Figure 8b ), and as with the results using ErbB3 siRNA, this was due to increase in apoptotic cells and to a lesser extent an increase in necrotic cells (Figure 8c ).
There was a 40% reduction in soft agar colonies when A549 cells were treated with Akt1 or Akt3 siRNA and a 60% reduction in soft agar colonies in Akt2.2 siRNAtreated cells (Figure 9a and b) . The amounts of Akt1, 2 and 3 proteins were correspondingly reduced in the cells used for the soft agar assay (Figure 9c ).
In sum, inhibition of Akt correlated with the effects of ErbB3 depletion in causing inhibition of cell growth, upregulation of apoptosis, necrosis and a reduction in anchorage-independent growth.
Akt2 and 3 depletions also reduce migration and invasion
Akt1 siRNA treatment had little effect in blocking the migration (Figure 10a and b) or invasion (Figure 10c and d) of A549 cells. Akt2 siRNA treatment remarkably downregulated both the migration (Figure 10a and b) and the invasion (Figure 10c and d) of A549 cells. Migration was reduced by 55% and invasion by 80%. Akt3 siRNA had more modest inhibitory effects on migration, about 20% (Figure 10a and b) , but was nearly as effective as Akt2 siRNA in suppressing cell invasion (Figure 10c and d) . These results suggest that the ErbB3 proliferation and survival pathway may include all three isoforms of Akt, whereas cell motility and invasion may function through Akt2/Akt3. Notably, Akt2 siRNA was the most effective in suppressing soft agar growth, migration and invasion.
ErbB3 and Akt siRNAs reduce Akt phosphorylation and cyclin D1 levels in Hrgb-stimulated cells
To confirm the hypothesized ErbB3 signaling through Akt in the above experiments with proliferating nonsynchronized A549 cells, we examined the effects of ErbB3 siRNA treatment on Akt under the same culture conditions. ErbB3 siRNAs 3.1 and 3.3 did not downregulate total Akt (not shown) or, surprisingly, pAkt levels (Figure 11a ). This experiment was repeated six times with the same outcome. As for the experiment illustrated in Figure 7b , interpretation is clouded by lack of antibodies specific for the different phosphorylated Akt isoforms. It is possible that a decrease in phosphorylated form of one or two Akt isoform was compensated by increase in the other(s). Or, the activation of Akt could involve tyrosine phosphorylation, Conus et al., 2002) . A third possibility is that these results could suggest that in proliferating A549 cells, activation of Akt3 is independent of ErbB3, and ErbB3 may exert survival signals independent of Akts. Further studies and additional reagents will be required to resolve these questions.
In the meantime, we tested further the connection between ErbB2/ErbB3 and Akt activation in the A549 cells, using a different approach: instead of nonsynchronized proliferating cells, we used serum-starved cells activated by treatment with the ErbB3 agonist Hrgb. We have demonstrated earlier that downstream of the ErbB2/ErbB3 heterodimer, activated Akt regulates the phosphorylation of Ser9 of GSK3b as well as expression of cyclin D1 to promote cell proliferation in these cells under conditions of stimulation after serum starvation (Sithanandam et al., 2003) . In the current experiment, we used the ErbB3 agonist Hrgb to stimulate the cells after serum starvation and to investigate the influence of ErbB3 and Akt siRNAs on this response. Hrgb (20 ng/ml) treatment of serum-starved A549 cells Figure 7 Isoform-specific inhibition of Akt proteins by corresponding siRNAs. (a) A549 cells were transfected with 120 pmol/ml of siRNAs specific for Akt1 (Akt1.1), Akt2 (Akt2.2) and Akt3. At 48 h after transfection, total cell lysates containing 20 mg protein were analysed by immunoblotting with total Akt antibody or Akt3-specific antibody. Mock and nonsilencing siRNA (NS) were used as controls. PI3K p85 used as a loading control showed equal loading (not shown). Akt1.1 reduced the band containing both Akt1 and Akt3 by about 50% (top) but did not reduce Akt3 (bottom panel). These results establish the isoform specificity of siRNAs Akt1.1, 2.2 and 3. (b) Reduction in basal Akt phosphorylation only by Akt3 siRNA. Total cell lysate containing 20 mg protein from Akt1, Akt2 or Akt3 siRNA-treated cells were analysed by immunoblotting with phospho-specific Ser473 Akt antibody. Data illustrated in all panels are representative of three separate experiments Figure 8 Decrease in viable cells and increase in apoptosis and necrosis by treatment with isoform-specific Akt siRNAs. All graphs show averages7s.e. from three independent experiments. (a) Reduction in percent living cells compared with mock transfectants by Trypan blue assay, 24 and 48 h after treatment with 120 pmol/ml Akt1.1, 2.2, or 3 siRNAs. All reductions were of statistical significance. (b) Percent dead cells by the Annexin V-FITC assay, 48 h after transfection. All increases vs the mock-transfected cells were of statistical significance. Apparent differences between Akt1.1 and Akt2.2 or Akt3 fell short of statistical significance (P ¼ 0.11 and 0.15, respectively). (c) Percent necrotic and apoptotic cells by the Annexin V-FITC assay, 48 h after transfection. All increases showed a statistical significance of Po0.05 or better, except for P ¼ 0.10 and 0.11 for increase in necrotic and apoptotic cells, respectively, after Akt3
ErbB3 and Akt siRNAs activity in lung adenocarcinoma cells G Sithanandam et al increased ErbB3/PI3K p85 association detected by coimmunoprecipitation (Figure 11b ). This was associated with an increase in pAkt at both 5 min and 5 h ( Figure  11c and e). Treatment with 50 ng/ml Hrgb also induced similar increase in pAkt (Figure 11d ). siRNAs ErbB3.1 and 3.3, and all three isoform-specific Akt siRNAs blocked this increase, at both 5 min and 5 h (Figure 11c e). siRNA-mediated depletion of ErbB2 also blocked Hrgb-induced Akt phosphorylation, suggesting that ErbB3 (ErbB3/ErbB2) heterodimer is involved in the regulation of Akt activation. Hrgb induced cyclin D1 upregulation (Figure 11f ). This increase was blocked by ErbB3 and Akt siRNAs activity in lung adenocarcinoma cells G Sithanandam et al siRNAs of ErbB3 or ErbB2 and by siRNAs of all isoforms of Akt. These data directly demonstrate an essential role for ErbB3 in the regulation of phosphorylation of Akt on Ser473 in cells stimulated by Hrgb after serum starvation, and confirm that ErbB3 is an important upstream regulator of Akt activation under these growth conditions. Also these results suggest that any of the isoforms of Akt could be involved in Hrgb/ErbB3/ErbB2-mediated cellular proliferation of A549 cells.
Discussion
The results presented here provide substantial evidence for major roles of ErbB3, and its downstream signaling target Akt, in proliferation, cell survival and invasion of lung adenocarcinoma cells. siRNA reagents proved to be effective experimental tools in this study, with longlasting effects, up to several days. siRNAs to ErbB3 and/or Akt could be useful for therapeutic approaches. ErbB3 siRNA treatment blocked both anchorageindependent and anchorage-dependent growth of A549 cells. This is consistent with our previous finding that ErbB3 antisense oligonucleotides blocked proliferation of H441 human lung adenocarcinoma cells (Sithanandam et al., 2003) . ErbB3 has also been implicated in oncogenic proliferation in other cancer types, for example, ErbB2-overexpressing breast cancer cells (Holbro et al., 2003) and ovarian cells (Gilmour et al., 2002) , and also for Hrgb-induced cellular proliferation and transformation of ErbB3/ErbB2-expressing NIH 3T3 cells (Vijapurkar et al., 2003) .
In addition to cell cycle suppression, reduction in ErbB3 by use of siRNA resulted in increased cell death, the first evidence that ErbB3 is involved in cell survival in lung adenocarcinoma cells. The majority of the cell death involved apoptosis, with also some increase in necrotic cells. ErbB3 downregulation from a variety of treatments has been shown to lead to increased apoptosis in colon and breast cancer cells Cho et al., 2003; Way et al., 2004) .
Also, notably established here for the first time is the importance of ErbB3 in the motility, migration and invasion of lung cancer cells; all of these properties were markedly suppressed by ErbB3 siRNAs. Stimulation of motility and migration appears to be an essential function of the ErbB2/ErbB3 complex in some systems, for example, development of the sympathetic nervous system (Britsch et al., 1998) . Contributions to breast cancer cell invasiveness have been noted (Hijazi et al., 2000) , and upregulation of ErbB3 along with ErbB2 and ErbB4 (but not EGFR) by ethanol (a risk factor for breast cancer) increased the invasiveness potential of breast cancer cells (Luo and Miller, 2000) . There is some evidence that these effects on cell behavior may be mediated locally, rather than indirectly through gene expression effects. The neuregulin-induced ErbB2/ ErbB3/PI3K pathway was shown to be essential for cell migration and invasion in glioma cells, and ErbB2 and ErbB3 were localized in lamellipodia (Ritch et al., 2003) . On the other hand, Hrg-induced ErbB2/ErbB3 heterodimer upregulated matrix metalloproteinase-9 expression (Xu et al., 1997) , which is essential in promoting invasiveness in A549 cells (Hauck et al., 2001) . Motility and invasiveness may be facilitated at several levels. These involvements of ErbB3 in promoting cell division, cell survival and motility/invasiveness are consistent with the finding that ErbB3 is associated with more aggressive lung tumors (Yi et al., 1997; Lai et al., 2001; Hilbe et al., 2003) .
Upstream control of ErbB3 is also of interest. We and others have observed production of Hrga and b, ErbB3 and Akt siRNAs activity in lung adenocarcinoma cells G Sithanandam et al upstream agonists of ErbB3, in lung adenocarcinoma cells (Sithanandam et al., 2003; Gollamudi et al., 2004) . In the present study, Hrgb, an agonist for ErbB3, caused increased Ser473 pAkt and cyclin D1 in serum-starved A549 cells, and this response was effectively blocked by siRNAs for ErbB3 and ErbB2, as well as all three Akt siRNAs. This is the first report linking Hrgb, ErbB3, pAkt and cyclin D1 in lung cells. In ErbB2-overexpressing breast cancer cells, downregulation of ErbB3 or of ErbB2 inhibited Akt phosphorylation and levels of cyclin D3 or cyclin D1 (Holbro et al., 2003; Basso et al., 2002) . Expression of constitutively active Akt rescued the proliferative block induced by ErbB3 depletion. Selective elimination of the ErbB3/PI3K pathway by site-directed mutation in ErbB2/ErbB3-overexpressing NIH3T3 cells eliminated Hrgb-dependent expression of cyclin D1 (Vijapurkar et al., 2003) .
Hrg was shown to be a mitogen in human fetal lung epithelial cells that express both ErbB2 and ErbB3 (Patel et al., 2000) and also in rat neonatal lung airway epithelial cells (Sundaresan et al., 1998) . In differentiated airway epithelia, Hrga was found exclusively in the apical membrane, whereas ErbB2 and ErbB3 were present in the basolateral membrane (Vermeer et al., 2003) . It was hypothesized that this spatial separation prevents interaction, until damage disrupts epithelial integrity, whereupon Hrg activation of ErbB3 sets in motion the cell division and migration processes essential for wound healing. Cancers may lose this control system present in the normal differentiated tissue. Autocrine activation of the ErbB2/ErbB3 receptor complex by Hrg in A549 cells was recently reported. An ErbB3-specific antibody, which blocked the Hrg binding sites on ErbB3, reduced endogenous ErbB2/ ErbB3 activation significantly (Gollamudi et al., 2004) .
Akt receives signals downstream of ErbB3 by virtue of the high affinity of active ErbB3 for the p85 regulatory subunit of PI3K, which in turn activates Akt. We have demonstrated this pathway in human lung adenocarcinoma cell line H441 (Sithanandam et al., 2003) . There is increasing evidence that the PI3K/Akt pathway is involved in proliferation and survival of small cell (Krystal et al., 2002) and non-small cell lung cancer cells and in poor lung cancer prognosis (Brognard et al., 2001; Tsao et al., 2003; Balsara et al., 2004; David et al., 2004; Okudela et al., 2004; West et al., 2004) . The present results confirm the key role that Akt plays in lung cancer cells, and are consistent with Akt mediating some of the observed effects of ErbB3, as siRNAs for all three Akt isoforms resulted in reduced proliferation and cyclin D1 levels, and increased apoptosis and necrosis, with patterns very similar to those seen with ErbB3. There were also some apparent differences among the Akt isoforms. In nonsynchronized growing cultures, only Akt3 siRNA reduced the level of Ser473 pAkt detected by a pan antibody, suggesting a prominence for this isoform and activation mechanism, under these conditions. Little is known about the specific properties of Akt3 (Bellacosa et al., 2004) . Akt1 and Akt2 siRNAs had effects on total Akt and on survival and invasiveness of the cells, but not on apparent levels of total Ser473 pAkt. Compensatory changes in other Akt isoforms, after one is blocked by siRNA, may be an explanation. Perhaps more likely, in these nonsynchronized cells, abundant autocrine production of TGFa, as well as Hrg, would insure high EGFR activation and possibly tyrosine phosphorylation of Akt1 and Akt2 as a predominant activation mode Conus et al., 2002) . This could also explain the observation that an effect of ErbB3 siRNAs on total Ser473 pAkt could not be detected.
Alternatively, some other upstream activator of Akt3 may be operative here. Akt3 is known to be activated by platelet-derived growth factor, insulin and insulin-like growth factor-1 (Sandirasegarane and Kester, 2001) .
For soft agar growth, Akt2 siRNA had a more pronounced inhibitory effect than siRNAs for Akt1 or Akt3. In the motility and invasion assays, Akt1 siRNA was without effect. Somewhat different results with regard to Akt1 were obtained in experiments with A549 cells involving dominant-negative Akt1 and overexpressed exogenous Akt1, both of which implicated Akt1 mediation of invasiveness (Okudela et al., 2004) . Akt1 antisense oligonuclotide treatment in lung adenocarcinoma cell H460 inhibited the anchorageindependent and anchorage-dependent growth and induced apoptosis and sensitized cancer cells to chemotherapeutic agents (Liu et al., 2001) . More experiments will be required to understand all of the contributions of Akt1 in lung cancer. Bitransgenic female mice expressing activated Akt1 and activated ErbB2 had mammary tumors with shorter latency period than mice expressing activated ErbB2 alone, but these tumors were poorly invasive and rarely metastasized (Hutchinson et al., 2004) , suggesting that Akt1 promoted tumorigenesis through increased cellular proliferation but interfered with subsequent metastatic progression by inducing epithelial differentiation.
Of the three Akt isoform-specific siRNAs, Akt2.2 was the most effective in suppressing invasion, bringing about 75% reduction relative to mock-transfected cells (Figure 10c and d) . In another recent study, wild-type Akt2 transfected into NSCLC increased their invasiveness, while dominant-negative Akt2 reduced this property (Balsara et al., 2004) . From these several experiments, Akt2 appears to be an especially attractive target for therapeutic approaches in lung cancer. Results from other cancer types are in agreement with this (Bellacosa et al., 2004) . Overexpression of Akt2 increased, and dominant-negative Akt2 decreased, the invasive potential of breast, ovarian, prostrate and pancreatic cancer cells (Arboleda et al., 2003) . Overexpressed Akt1 or Akt3 did not have these effects. Akt2 antisense suppressed invasion of pancreatic cancer cells and blocked tumor formation in nude mice (Arboleda et al., 2003) . These Akt2-specific events appeared to be related to the fact that Akt2, but not Akt1, is localized in regions of cell-cell and cell-matrix interactions, as determined by specific pleckstrin homology domains (Arboleda et al., 2003) . There is evidence for specific upregulation of Akt2 in human liver (Vermeer et al., 2003) and colorectal (Roy et al., 2002) cancer.
As noted above, ErbB3 siRNA appeared not to block activation of Ser473 pAkt3 in nonsynchronized proliferating A459 cells, even while suppressing growth and increasing apoptosis, although as noted above unanswered questions remain regarding the possibility of compensatory changes among the isoforms and/or other Tyr activation sites for Akt under these growth conditions. If further studies confirm this finding, Aktindependent alternatives will have to be considered and investigated. A reasonable guess is that NF-kB could be involved, since NF-kB activation is known to contribute to expression of proteins that promote apoptosis or inhibit apoptosis depending upon the stimulus and the cell type (Shishodia and Aggarwal, 2004) . NF-kB activation induced apoptosis in lung cancer cells including A549 . In preliminary experiments, we in fact observed that phospho-IkB-a (Ser32) also increased in ErbB3 siRNA-treated A549 cells compared to the mock and untreated control cells (data not shown); this phosphorylation of the inhibitory IkB would result in its degradation and NF-kB activation. It is tempting to speculate a role for NF-kB activation in the proapoptotic effect of ErbB3 knockdown in A549 cells. NF-kB activation in the presence (Romashkova and Makarov, 1999; Ozes et al., 1999) and absence of Akt phosphorylation (Van Antwerp et al., 1996; Taylor et al., 2004) has been reported. In A549 cells, PI3K/Akt and NF-kB may function as independent survival mechanisms operative under different cellular growth contexts.
Collectively these data confirm that ErbB3 is involved in lung cancer cell proliferation and further demonstrate that ErbB3 is essential for cell survival and invasion. The three Akt isoforms may have both common and distinct roles downstream of ErbB3. The results are consistent with the intriguing suggestion that, in the integrated regulatory control system of lung epithelium, the Hrg/ErbB2/ErbB3 path serves as the primary trigger for proliferation, migration and suppression of apoptosis (Vermeer et al., 2003) . EGFR is probably also important but perhaps as a secondary modulator. ErbB3 would seem to be a critical primary target for development of lung cancer therapies, perhaps in conjunction with EGFR, ErbB2 and/or Akt targeting, and/or chemotherapy. Our results show that siRNA to these molecules may have potential therapeutic utility.
Materials and methods

Cell lines and culture conditions
Human lung adenocarcinoma cell lines A549, H441 and H1373 were obtained from American Type Culture Collection and were cultured in RPMI 1640 medium (Biofluids, Rockville, MD, USA) supplemented with 1% penicillin/streptomycin, 2 mM glutamine and 10% fetal calf serum (FCS; PAA Laboratories, Parkerford, PA, USA). Recombinant human heregulin beta (Hrgb) was obtained from R&D (Minneapolis, MN, USA). Results showing downregulation of pAkt3 were confirmed with use of two of these sequences, GGAGUAAAC UGGCAAGAUGUU and GACAUUAAAUUUCCUCGA AUU (data not shown). Nonsilencing control siRNA was from Qiagen: sense UUCUCCGAACGUGUCACGUdTT; antisense ACGUGACACGUUCGGAGAAdTT (GenBank search showed no identities except for a 16-base overlap with a gene from the bacterium Thermotoga maritimia). For most experiments, approximately 2 Â 10 5 cells were plated in six-well plates in medium containing 10% FCS and cultured for 24 h to give 60-75% confluence and then were transfected with siRNA at the indicated concentrations. Other experimental conditions are given in the figure legends. Transmessenger transfection reagent from Qiagen was used for transfections and was used as per the manufacturer's instructions. The cells were analysed 24-72 h after siRNA transfection.
Immunoblotting
Cultured cells for immunoblots were rinsed with cold phosphate-buffered saline (PBS, 17 mM KH 2 PO 4 , 50mM Na 2 HPO 4 and 150 mM NaCl) and scraped in lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mg/ml leupeptin (Cell Signaling Technology, Beverly, MA, USA) and supplemented with 1 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co., St Louis, MO, USA) just before use.
For immunoblotting, the cell lysates were loaded at the protein concentration indicated in the figure legends on Trisglycine gels (Invitrogen, Carlsbad, CA, USA), 6% gels for growth factor receptors, and 8 or 12% gels for Akt and cyclin D1, and electrophoresed at 100 V. After transfer to Hybond nitrocellulose membranes (Amersham, Buckinghamshire, UK) at 22 V at room temperature, the blots were blocked either in 3% bovine serum albumin or 3-5% dried milk for 2 h at room temperature and probed overnight with antibodies. Antibodies to ErbB2, ErbB3, Akt3, PI3K p85 polyclonal and cyclin D1 were from Upstate Biotechnology (Lake Placid, NY, USA). Antibodies to Akt (all isoforms), phospho-ser473Akt (a pan antibody) and cleaved PARP were from Cell Signaling Technology. Detection of the bound antibody was by ECL (Amersham). Antibody dilutions for immunoblotting were 1 : 1000. The blots were stripped in buffer containing 100 mM 2-mercaptoethanol, 2% sodium dodecyl sulfate and 65 mM Tris, pH 6.8, for 30 min at 601C and washed for 1 h with PBS plus 0.1% Tween 20 before reprobing with another antibody.
Determination of cell numbers and viability
A total of 200 000 cells were seeded per well into six-well tissue culture plates and 48 h post-transfection with siRNA, the cells were harvested and aliquots stained with 0.4% Trypan blue in PBS (Invitrogen). Cells were counted with a hemacytometer (5-10 fields/sample).
The MTT (3-(4,5-dimethylthiazol 2-yl)-2,5-diphenyltetrazolium bromide) assay was also used to assess cell numbers, using a kit from Roche Applied Sciences (Indianapolis, IN, USA). Cells (5 Â 10 3 ) were plated in 96-well plates and incubated for 24 h. Following siRNA transfection, cells were incubated for an additional 48 h and assayed for the number of viable cells as per the manufacturer's instructions. Substrate cleavage was monitored at 570 nm using a Biotech microplate reader. Assays were repeated twice.
Apoptosis assays
Cells were treated with siRNA as described in the figure legends; 24 or 48 h after siRNA treatment, floating cells were collected and adherent cells were trypsinized, washed twice with ice-cold PBS, resuspended in PBS and fixed by adding absolute ethanol to a final concentration of 70% and left at À201C. The day before the flow cytometric analysis (FACS), cells were washed with PBS and resuspended in PBS and the cell nuclei were stained in the dark with 100 mg/ml PI (Sigma) containing 125 U/ml RNase and left overnight at 41C. The next morning, a total of 10 000 stained nuclei were analysed in a Coulter XL flow cytometer, using system II version 3.0 software.
Cells were stained with Annexin V-FITC and PI according to the manufacturer's instructions using the Annexin V-FITC kit from Oncogene Research Products (San Diego, CA, USA). The percentage of apoptotic cells was also quantified by FACS after fluorescent staining with Annexin V-FITC and PI. Annexin-V-positive cells undergoing apoptosis and PI-positive cells undergoing necrosis were detected by FACS.
Soft agar assay
At 24 h after siRNA transfection, 1 Â 10 5 cells were resuspended in medium containing 0.3% low-melting agarose, which was layered on top of a solidified 0.5% agarose bottom layer in 35 mm tissue culture plates in duplicate. These assays were carried out with 10% FCS. After 15 days of incubation, the colonies were stained with p-iodonitrotetrazolium violet and the images were captured using a Sony camera fitted to a Olympus CK-2 microscope. The numbers of colonies were quantified using Image-Pro Plus software from Media Cybernetics (Silver Spring, MD, USA). Soft agar assays were performed three times.
Cell spreading
siRNA-transfected cells were plated on thin-or thick-layer Matrigel-coated 24-well plates (BD Biosciences, Bedford, MA, USA) and incubated at 371C for 6-12 h. Spreading cells were defined as cells with extended processes and unspread cells were defined as round cells.
Migrations and invasion assays
At 24 h after transfection, cells were trypsinized and resuspended in 0.1% serum containing RPMI media with 0.5% bovine serum albumin. A total of 5 Â 10 4 cells in 0.3 ml media were plated in the upper chambers in duplicate filters. The migration assay utilized transwell chambers with tissue culture inserts containing an 8 mm pore size tracked-etched polyethylene terephthalate (PET) membrane (BD Biosciences). The membrane invasion assay was performed in similar chambers, where the PET membrane was coated with Matrigel. RPMI medium with 10% serum was used as a chemoattractant in the lower chamber. After 18 h incubation at 371C, the cells on the upper surface of the membrane were mechanically removed with a cotton swab. For both assays, the migratory or invading cells were fixed in 100% ice-cold methanol and stained with Giemsa (1 : 25 in phosphate buffer (pH 6.6)). They were examined and photographed by microscopy (Olympus AX70 Microscope) with an Axio Cam camera. A total of 3-5 fields (each 0.81 mm 3 ) were counted per filter. The experiment was repeated three times.
Statistical analyses
All experiments were repeated 3-8 times. Replicates (usually duplicate or triplicate samples) from each experiment were averaged before statistical analysis. Data were analysed with software from GraphPad Instat version 3.00 for Windows (GraphPad Software, San Diego, CA, USA). Tests included analysis of variance, paired and unpaired t-tests, and the Kruskal-Wallis nonparametric test, as appropriate. Two-tailed P-values of o0.05 were regarded as significant.
